Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Anta Sports Expands Global Footprint With Strategic Puma Stake 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
LAWRENCEVILLE, N.J., March 12, 2018 -- -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced that Michael Tardugno, Chairman, President and Chief Executive Officer, will present at the following upcoming investor conferences:
- The B. Riley FBR Inaugural China Healthcare Investing & Partnering Symposium (CHIPS) on Friday, March 16, 2018 at 3:30 p.m. local time. The conference will be held March 15-17, 2018 at The InterContinental Hotel Hangzhou, China.
- The Oppenheimer 28th Annual Healthcare Conference on Tuesday, March 20, 2018 at 9:10 a.m. EDT. The conference will be held March 20-21, 2018 at The Westin New York Grand Central in New York City.
A live webcast of Celsion’s presentation at the Oppenheimer conference may be accessed by visiting the “News & Investors” section of Celsion’s corporate website at www.celsion.com. A replay of the webcast will also be available and archived on the site for 90 days following the presentation or until June 19, 2018.
About Celsion Corporation
Celsion is a fully-integrated oncology company focused on developing a portfolio of innovative cancer treatments, including directed chemotherapies, immunotherapies and RNA- or DNA-based therapies. The Company's lead program is ThermoDox®, a proprietary heat-activated liposomal encapsulation of doxorubicin, currently in Phase III development for the treatment of primary liver cancer and in Phase II development for the treatment of recurrent chest wall breast cancer. The pipeline also includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian and brain cancers. Celsion has two platform technologies for the development of novel nucleic acid-based immunotherapies and other anti-cancer DNA or RNA therapies. For more information on Celsion, visit our website: www.celsion.com. (CLSN-FIN)
ThermoDox® is a registered trademark of Celsion Corporation.
Celsion Investor Contact Jeffrey W. Church Sr. Vice President and CFO 609-482-2455 [email protected]
